ONCI Archives - Page 3 of 3 - Blue Horseshoe Stocks

Blue Horseshoe Stocks: Earnings Calls, Bottom-Plays & More

Momo, Inc. MOMO

We began tracking MOMO on Friday after noticing the stock coming off of a bottom, and we’ve seen an appreciable move to the upside in the ensuing sessions.

The stock is gapping up this morning on a strong earnings report (>>View Highlights), reaching a high of 12.73 in the premarket. We caught MOMO at a low of 11.52 on Friday and have thus far seen an 11% increase, so we’ll want to leave it on the radar and watch for higher lows and higher highs.

NQ Mobile, Inc. NQ

Speaking of earnings plays, we’re going to be tracking NQ closely over the next couple of sessions. The stock has been trending off of a bottom for the past three sessions and this morning, we’re seeing the stock gap up considerably.

Things are likely to get interesting as the company is slated to release earnings post-market today, and a big PR hit wires just an hour ago.

Today’s News: NQ Mobile Inc. Enters into a Definitive Agreement for the FL Mobile Divestment (>>View PR)

Hercules Offshore, Inc. HERO

We’re also going to be monitoring HERO, which, like the aforementioned stock, has been establishing a solid move up off of recently-registered two-month lows.

As you can see on the included snapshot of the chart, HERO went on a massive run from the .70-range to more than 4.00 from February to April. Indicators are ripening for what could be the next big leg up after the recent consolidation, so we’ll be sure to keep an eye peeled for the possibility of a continued upsurge.

The Children’s Place, Inc. PLCE

PLCE is yet another bottom-bouncer with earnings that is gapping up in early trading. We’re going to signal a range of options contracts for observation to possibly take advantage of the momentum. Our target range is going to be the PLCE Weekly $70-75 Calls.

Chatroom Call:

Our daily live traders chats are a great way to get involved with what we do. Regular participant DJ spotted another big runner and shared with the room shortly after the opening bell. We saw it at .03 before it went on a monumental run to hit a high of .465 on news with TOMS Shoes. Gains of over 1500% were possible. Feel free to join our traders chats by sending a Skype request to user ‘stocksumo’.

Extended Watchlist:
AMMX, ONCI, KGNX, OREX, LIVE, KGJI

DRRX, PPHM & Extended Watchlist

Durect Corp. DRRX

We are putting DRRX on our radar this morning; it has recently come off of a bottom, and is gaining some momentum as it begins its recovery. Prior to May, this pharmaceutical play was trading at a base level well above 1.20, before seeing a large spike followed by a sharp dropoff. If DRRX can break through resistance at the 50DMA & 200DMA there’s a chance it could come up to fill that gap on the chart. A return to previous levels from here could yield gains of up to 20%

In addition to a connection with pharma giant Pfizer, the company has also gotten FDA acceptance of a New Drug Application (NDA) as outlined in yesterday’s PR:

CUPERTINO, Calif., June 20, 2013 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. POSIDUR is a post-operative pain relief depot that utilizes DURECT’s patented SABER technology to deliver bupivacaine and is designed to provide up to three days of pain relief after surgery. DURECT submitted the NDA as a 505(b)(2) application. The Prescription Drug User Fee Act (PDUFA) goal date (the date the FDA expects to complete its review of the NDA) has been confirmed as February 12, 2014.

Peregrine Pharmaceuticals, Inc. PPHM

Speaking of pharmaceutical plays, one of the stocks that we continuously monitor is PPHM. Many of you will remember back in May when the stock provided us with some serious opportunities for profit.

Recently PPHM has been in a marked downtrend, and as you can see on the chart below, indicators seem to confirm this fact. We are going to want to put this one on bottom watch over the next several sessions, as the resulting bounce/s could be significant.

Side Note:

Since Ben Bernanke’s recent comments regarding the Fed’s upcoming tapering of quantitative easing measures, markets have been in freefall. If no reversal occurs and that remains the overall trend, we are going to want to keep an eye on SPY Puts, VIX/VXX Calls.

Extended Watchlist:
ONCI, ONCO, LIVE, KERX, MSTX

BMSN, KERX & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

BMSN has been a main point of focus for us this year. We first began paying close attention to BMSN towards the end of 2012 when it was trading as low as .0003. Yesterday, the stock had another rockstar performance, reaching new highs and cracking through another major resistance point at .0035 (200DMA).

After the initial surge we saw from .0003-.0024, we wanted to see support hold off of .001. Now that we have hit new highs, we are raising the bar and looking for new support to hold at .0035, or below that, the 20DMA of .0021. If we can see these areas hold as support, we are going to remain bullish on BMSN.

Over the span of our coverage on BMSN, we have been afforded the opportunity at an accumulation of up to 1400% in possible gains from .0003 to yesterday’s high of .0045

Most Recent News:

SAN DIEGO, CA, Jan 24, 2013 (MARKETWIRE via COMTEX) — Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate(TM) bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.

Keryx Biopharmaceuticals, Inc. KERX

KERX earned us a spot in the Penny Stock Rumble on Tuesday, racking up another solid day of gains, and hitting a high of 8.79. That brings our total possible profits to a very respectable 154%

We are going to be monitoring the activity on KERX following yesterday’s announcement regarding the comnpany’s planned $55M public offering.

Yesterday’s News:

NEW YORK, Jan. 29, 2013 /PRNewswire via COMTEX/ — Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering.

Extended Watchlist:
SCXN, ITNS, MYRY, SWVI, ONCI, ENTB